University of Iowa Hospitals and Clinics

Clinical Research Studies

Eligibility

Gender



Age Group



More options for age range

Dates

Clinical Research started within last

Names

Principal Investigator

Showing 1 - 5 of 11 results
Page 1 of 3   

Brain Study

Principal Investigator
Daniel O'Leary, PhD
Department
Department or Field of Study

Adolescents between the ages of 13-18 (who are still in jr. high or high school) with no family history of alcohol problems are invited to participate in a research study investigating brain development conducted at the Department of Psychiatry. 

Study will last 1-2 visits and involve filling out forms, saliva sample, cognitive testing and an MRI scan (no radiation).  Parents will be asked to fill out family history forms.  Additionally, both parents should have no more than a 4 year college degree.  Compensation available. 

For more information, call (319) 353-8520 or email brain-lab@uiowa.edu

age group:13 to 18 years trial start date:January 1, 2014
Gender Preference:none Trial End Date: January 1, 2015
Contact Info:

Call (319) 353-8520 or email brain-lab@uiowa.edu

Keywords: brain development ; pediatric ; psychiatry ; substance use and addictive disorders

Brain Study

Principal Investigator
Daniel O'Leary, PhD
Department
Psychiatry

Adolescents between the ages of 13-18  (who are still in jr. high/high school) with at least 1 biological parent who has a history of alcohol treatment/addiction/problems related to use are invited to participate in a research study investigating brain development conducted at the Department of Psychiatry.  

Study will last 1-2 visits and involves filling out forms, saliva sample, cognitive testing and an MRI scan (no radiation).  Guardians will be asked to fill out family history forms.  Compensation available.  For more information, call (319) 353-8520 or email brain-lab@uiowa.edu

This study is being conducted by the University of Iowa Department of Psychiatry.

age group:13 to 18 years trial start date:January 1, 2014
Gender Preference:none Trial End Date: January 1, 2015
Contact Info:

E-mail: brain-lab@uiowa.edu

Phone Number: 319-353-8520

Toll Free Number: 1-877-575-2864



Keywords: brain development ; pediatric ; psychiatry ; substance use and addictive disorders

Oral LDE225 Versus Temozolomide in Patients With Hh-pathway Activated Relapsed Medulloblastoma

Principal Investigator
Sue O'Dorisio, MD, PhD
Department
Pediatrics Academic Administration

Participants in this research study have relapsed medulloblastoma and will receive the drug LDE225 or Temozolomide. The purpose of the study is to find out if the drug LDE225 is safe and has more beneficial effects in people who have relapsed medulloblastoma compared to the drug Temozolomide. LDE225 is an investigational drug being developed by Novartis, the Sponsor, for the treatment of cancer. Temozolomide is a medication that is indicated for the treatment of patients with certain brain tumors.

About 109 patients from about 89 sites in North America, Europe, Australia and Latin America will be enrolled into this study.

age group:0 to 99 years trial start date:December 12, 2013
Gender Preference:none Trial End Date: January 1, 2018
Contact Info:

Joan Kempf, (319) 384-5280

Keywords: 201304508 ; cancer ; medulloblastoma ; O ; pediatric ; Phase three

Clinical Trial Readiness for the Dystroglycanopathies

Principal Investigator
Katherine D. Mathews, MD

In this project, researchers will examine the clinical presentation of muscular dystrophy caused by abnormal glycosylation of alpha-dystroglycan. Patients with dystroglycanopathies could have mutations in one of the following genes: FKRP, fukutin, POMT1, POMT2, POMGnT1 or LARGE. Symptoms range from congenital muscular dystrophy that can also involve the brain and eye, through an adult-onset limb girdle muscular dystrophy. The purpose of the study is to describe the early signs and symptoms of the dystroglycanopathies, and to gather information that will be required for future clinical trials. Knowledge gained from this study will improve the health care recommendations for people with dystroglycanopathies, and provide a baseline for further study.

 The study involves a clinical evaluation at theUniversityofIowa. The evaluation includes muscle strength and motor ability testing, lung function testing, quality of life and activity assessment, and a review of past medical history. Portions of this evaluation will be repeated on a yearly basis.  Financial assistance is available for travel toIowa City. Support is also available for genetic testing for people with a dystroglycanopathy diagnosis based on muscle or skin biopsy analysis.

age group:0 to 80 years trial start date:July 1, 2011
Gender Preference:none Trial End Date: July 31, 2015
Contact Info:

This study is sponsored by the National Institutes of Health and is being directed by Dr. Katherine Mathews at the Universityof Iowa. If you are interested in participating or would like additional information, please contact the study coordinator Carrie Stephan R.N. by phone at (319) 356-2673 or by email at carrie-stephan@uiowa.edu

Keywords: Dystroglycanopathy ; Neurology ; Pediatric

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

Principal Investigator
Ayman El-Sheikh, MD

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

AML is a cancer of the bone marrow, the spongy tissue inside the large bones of the body where blood cells are made. In AML, the bone marrow makes large numbers of immature white blood cells called blasts. These blast cells crowd out the normal cells of the bone marrow. They may also invade body organs including the brain, testes, ovaries, or skin. These cancerous AML cells can sometimes form a solid tumor called a chloroma.

The main goals of this study are:

For subjects without high amounts of the FLT3 gene mutation,

1.  To see if an investigational drug, called bortezomib, is tolerated when added to the standard AML treatment without causing too many serious side effects.

2. To compare the effects, good and/or bad, of adding bortezomib to the standard AML treatment to find out which is better. In this study, you will get either the standard treatment plus bortezomib or the standard treatment alone.

For subjects with high amounts of the FLT3 gene mutation,

3. To determine the dose of sorafenib that can be safely given with the standard AML treatment.

4. To compare the effects, good and/or bad, of adding sorafenib to standard AML treatment to find out which is better.

5. To determine how effective the combination of sorafenib and chemotherapy will be at killing cancer cells.

Approximately 5 people will take part in this study conducted by investigators at the University of Iowa. The total number of people enrolled on this study nationally is expected to be 1250.

age group:0 to 29 years trial start date:June 20, 2011
Gender Preference:none Trial End Date: June 20, 2016
Contact Info:

Julie de la Garza, (319) 356-3749

Keywords: acute myeloid leukemia (AML) ; bortezomib ; cancer ; children ; pediatric ; phase III ; sorafenib
Page 1 of 3
« 1 2 3 » 
Results per page

Clinical Research Studies

Filters

Your Selections

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.